Table 2

Change in cell marker expression following treatment in the responder and non-responder groups

Week 0

Week 12

P-value

CD3

etanercept

R n = 12

27.5 (6.5 to 1121)

16 (0.5 to 113)

0.05*

NR n = 1

17

14

n/a

anakinra

R n = 4

33.5 (1 to 1344)

32.9 (3 to 734)

0.47

NR n = 4

87.9 (13 to 265)

300 (166 to 389)

0.068

CD68sl

etanercept

R n = 12

127 (138 to 3,543)

712 (112 to 2,318)

0.31

NR n = 1

1,408

1,667

n/a

anakinra

R n = 4

1,370 (362 to 2,685)

1,444 (453 to 2,414)

0.72

NR n = 4

1,431 (494 to 1,795)

1,879 (1,741 to 2,218)

0.068

CD68ll

etanercept

R n = 12

226 (38 to 513)

213 (17 to 466)

0.48

NR n = 1

191

150

n/a

anakinra

R n = 4

174 (129 to 469)

214 (154 to 473)

0.47

NR n = 4

159 (108 to 197)

147 (104 to 319)

0.72

FVlll

etanercept

R n = 11

132,242 (43,272 to 754,550)

139,294 (51,817 to 439,712)

0.53

NR n = 1

58,525

142,834

n/a

anakinra

R n = 4

218,619 (88,372 to 353,725)

280,785 (226,415 to 353,725)

0.27

NR n = 4

286,939 (84,419 to 521,103)

437,447 (184,155 to 545,675)

0.72

MRI

etanercept

R n = 13

8 (4 to 12)

5 (2 to 11)

0.12

NR n = 1

3

1

n/a

anakinra

R n = 5

4 (4 to 12)

4 (4 to 9)

0.66

NR n = 3

4 (0 to 11)

4 (4 to 7)

1

Median (range). n/a, not applicable; NR, non-responder; R, responder

Pontifex et al. Arthritis Research & Therapy 2011 13:R7   doi:10.1186/ar3228